Preferred Label : Sodium-Glucose transporter 2;
MeSH definition : A sodium-glucose transporter that is expressed in the luminal membrane of the PROXIMAL
KIDNEY TUBULES.;
MeSH synonym : sglt2 protein; slc5a2 protein; sodium glucose transporter 2;
Wikipedia link : https://en.wikipedia.org/wiki/Sodium-glucose transporter 2;
Is substance : O;
Origin ID : D051297;
UMLS CUI : C1565154;
ATC code(s)
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Indexing information
Record concept(s)
Related MeSH Supplementary Concept(s)
Related MeSH term(s)
See also (suggested by CISMeF)
See also inter- (CISMeF)
Semantic type(s)
A sodium-glucose transporter that is expressed in the luminal membrane of the PROXIMAL
KIDNEY TUBULES.
https://www.revmed.ch/RMS/2017/RMS-N-565/Association-des-analogues-du-GLP-1-et-des-inhibiteurs-du-SGLT2-de-nouvelles-perspectives
2018
false
false
false
Switzerland
French
journal article
administration, oral
hypoglycemic agents
diabetes mellitus, type 2
switzerland
treatment outcome
body weight
cardiovascular diseases
drug therapy, combination
GLP-1 Mimetics
glucagon-like peptide 1
Glucagon-like peptide-1 (GLP-1) analogues
SGLT2 Inhibitor
Sodium-Glucose transporter 2
dulaglutide
Liraglutide
empagliflozin
dapagliflozin
Canagliflozin
blood glucose
arterial pressure
genetic pleiotropy
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
peptides
venoms
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
benzhydryl compounds
glucosides
Exenatide
---
https://www.revmed.ch/RMS/2017/RMS-N-571/Inhibiteur-de-la-DPP-4-ou-des-SGLT2-apres-echec-de-la-metformine-seule-dans-le-diabete-de-type-2
2018
false
false
false
Switzerland
French
journal article
dipeptidyl-peptidase iv inhibitors
Sodium-Glucose transporter 2
SGLT2 Inhibitor
diabetes mellitus, type 2
metformin
treatment outcome
drug therapy, combination
dipeptidyl peptidase 4 (DPP-4) inhibitors
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Sodium-Glucose Transporter 2 Inhibitors
---
https://www.revmed.ch/RMS/2017/RMS-N-565/Acidocetose-euglycemique-une-complication-des-inhibiteurs-du-SGLT2
2018
false
false
false
Switzerland
French
administration, oral
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Product containing sodium glucose cotransporter subtype 2 inhibitor (product)
SGLT2 Inhibitor
Sodium-Glucose transporter 2
Canagliflozin
hypoglycemic agents
empagliflozin
dapagliflozin
ketosis
journal article
practice guidelines as topic
precipitating factors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
benzhydryl compounds
glucosides
---
https://rmlg.uliege.be/article/2974
2018
false
false
false
false
Belgium
French
journal article
diabetes mellitus, type 2
cardiovascular diseases
hypoglycemic agents
empagliflozin
treatment outcome
empagliflozin
Sodium-Glucose transporter 2
comparative effectiveness research
Liraglutide
liraglutide
Glucagon-Like Peptide-1 Receptor
incretins
case reports
prognosis
cardiovascular diseases
drug therapy, combination
diabetes mellitus, type 2
renal insufficiency, chronic
belgium
insurance, health, reimbursement
Clinical Decision-Making
risk factors
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
glucosides
---
https://www.revmed.ch/RMS/2017/RMS-N-571/Options-therapeutiques-chez-un-patient-diabetique-de-type-2-mal-controle-par-une-insuline-basale
2017
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
administration, oral
insulin
injections, subcutaneous
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
Sodium-Glucose transporter 2
drug therapy, combination
Glucagon-Like Peptide-1 Receptor
drug combinations
Sodium-Glucose Transporter 2 Inhibitors
---
SGLT2 inhibitors
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-12-fra.php#sglt2
2016
false
false
false
Canada
French
English
drug evaluation
SGLT2 Inhibitor
Sodium-Glucose transporter 2
Canagliflozin
hypoglycemic agents
risk assessment
dapagliflozin
empagliflozin
diabetes mellitus, type 2
fractures, bone
bone demineralization, pathologic
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
---
https://rmlg.uliege.be/article/2854
2016
false
false
false
Belgium
French
journal article
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
dipeptidyl peptidase 4 (DPP-4) inhibitors
Sodium-Glucose transporter 2
comparative effectiveness research
renal insufficiency
other blood glucose lowering drugs, excl. insulins
---
https://smf.swisshealthweb.ch/fr/article/doi/fms.2016.02684/
2016
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
practice guidelines as topic
glucagon-like peptide 1
GLP-1 Mimetics
GLP-1 Mimetics
dipeptidyl-peptidase iv inhibitors
cardiovascular diseases
obesity
Sodium-Glucose transporter 2
SGLT2 Inhibitor
SGLT2 Inhibitor
insulins
risk factors
weight loss
hypoglycemia
insulins
hypoglycemic agents
Sodium-Glucose Transporter 2 Inhibitors
---
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58404a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
Sodium-Glucose transporter 2
SGLT2 Inhibitor
Canagliflozin
hypoglycemic agents
dapagliflozin
metformin and dapagliflozin
drug combinations
metformin
empagliflozin
diabetic ketoacidosis
guidelines for drug use
diabetes mellitus, type 2
risk factors
dapagliflozin
canagliflozin
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
---
https://smf.swisshealthweb.ch/fr/article/doi/fms.2016.02616/
2016
false
false
false
Switzerland
French
review of literature
administration, oral
SGLT2 Inhibitor
Sodium-Glucose transporter 2
diabetes mellitus, type 2
glycosuria
urinary tract infections
risk factors
candidiasis, vulvovaginal
balanitis
candidal balanitis
hypoglycemic agents
candidiasis, vulvovaginal
balanitis
urinary tract infections
SGLT2 Inhibitor
Sodium-Glucose Transporter 2 Inhibitors
---
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin)
- Assessing the Potential Risk of Bone-Related Side Effects
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/sglt2-3-fra.php
2016
false
false
false
Canada
French
English
Canagliflozin
hypoglycemic agents
dapagliflozin
Sodium-Glucose transporter 2
SGLT2 Inhibitor
risk assessment
drug evaluation
empagliflozin
adult
diabetes mellitus, type 2
fractures, bone
bone demineralization, pathologic
bone and bones
pharmacovigilance note
product surveillance, postmarketing
canada
dapagliflozin
canagliflozin
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
benzhydryl compounds
glucosides
---
http://www.revmed.ch/RMS/2015/RMS-N-477/Analogues-du-GLP-1-versus-inhibiteurs-du-SGLT-2-pour-les-diabetiques-de-type-2-obeses
2015
false
false
false
Switzerland
French
diabetes mellitus, type 2
obesity
comparative effectiveness research
treatment outcome
incretins
hypoglycemic agents
Liraglutide
glucagon-like peptide 1
Canagliflozin
Sodium-Glucose transporter 2
SGLT2 Inhibitor
dapagliflozin
empagliflozin
1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol
other blood glucose lowering drugs, excl. insulins
GLP-1 Mimetics
journal article
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
peptides
venoms
sorbitol
sorbitol
Exenatide
---
http://www.revmed.ch/RMS/2015/RMS-N-463/Les-inhibiteurs-du-cotransporteur-SGLT2-comme-nouveau-traitement-du-diabete-aspects-renaux
2015
false
false
false
Switzerland
French
journal article
kidney, nos
new
Sodium-Glucose transporter 2
therapeutics
diabetes mellitus
with pattern
---
https://minerva-ebp.be/fr/article/1088
2015
false
false
false
minerva-ebm.be
Belgium
French
critical appraisal or critical reading
diabetes mellitus, type 2
Sodium-Glucose transporter 2
treatment outcome
hypoglycemic agents
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
---
http://www.amub-ulb.be/revue-medicale-bruxelles/article/les-nouveaux-anti-diabetiques-oraux-1032
2014
false
false
false
false
Belgium
French
journal article
comparative study
diabetes mellitus, type 2
incretins
hypoglycemic agents
administration, oral
incretins
gastric inhibitory polypeptide
glucagon-like peptide 1
dipeptidyl-peptidase iv inhibitors
dipeptidyl peptidase 4 (DPP-4) inhibitors
other blood glucose lowering drugs, excl. insulins
incretins
hypoglycemic agents
hypoglycemic agents
SLC5A2 protein, human
risk factors
drug therapy, combination
treatment outcome
Glucagon-Like Peptide-1 Receptor
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose transporter 2
---
http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=FR&Expert=69076
2006
France
French
rare diseases
Sodium-Glucose transporter 2
glycosuria, renal
scientific and technical information
---